Jade Biosciences Q2 net loss $32.1M; cash $220.9M; JADE101 Phase 1 starts Q3

Jade Biosciences, Inc.

2025-Q2 EPS reported -$3.45

Net loss of $32.1M for Q2 2025; R&D expense $22.5M, G&A $5.2M; non-cash stock comp $4.0M.
Cash and cash equivalents of $220.9M as of June 30, 2025; expected runway through 2027.
JADE101 preclinical data presented; Phase 1 healthy-volunteer study to begin Q3 2025 with interim data H1 2026.
Appointed Brad Dahms as CFO; previously CFO at IDRx, Theseus, Selecta.
JADE201 development candidate from JADE-002 program on track for clinic in H1 2026; details expected H2 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.